Result of AGM

RNS Number : 8546S

Polarean Imaging PLC

13 July 2020

 

Polarean Imaging Plc  

("Polarean" or the "Company")

Result of AGM

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company, with a proprietary drug‑device combination product for the magnetic resonance imaging (MRI) market, announces that at the AGM held earlier today, all resolutions were duly passed.  

Details of the proxy votes received on each resolution by Polarean's Registrar are set out below:

Resolution	For	Against
Resolution 1	69,040,651	0
Resolution 2	69,035,550	5,101
Resolution 3	69,040,651	0
Resolution 4	69,040,651	0
Resolution 5	69,040,651	0
Resolution 6	69,040,651	0
Resolution 7	69,010,651	0
Resolution 8	68,885,651	125,000

Contacts:

Polarean Imaging plc	www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Officer  Jonathan Allis, Chairman	Via Walbrook PR
SP Angel Corporate Finance LLP  Nomad and Broker			Tel: [phone]
David Hignell / Soltan Tagiev (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Walbrook PR	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone]

About Polarean ( www.polarean.com )

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical drug-device combination companies operating in the high-resolution medical imaging market.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (¹²⁹Xe) as an imaging agent to visualize ventilation.¹²⁹Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung, and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging ¹²⁹Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimize the imaging of ¹²⁹Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

 

END

 

 

RAGSFSFDDESSEEW